Internationale Verbundprojekte

Hier erhalten Sie einen Überblick über internationale Verbundprojekte, in die unsere RCIS-Mitglieder involviert sind.


The One Study

"A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation"


"Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective. New transplant research should concentrate on early strategies that support long-term immunological acceptance of transplants, allowing for at least a reduction in the use of general immunosuppression. It would dramatically improve the outcome for transplant recipients and reduce healthcare costs.

The ONE Study applies the novel concept of cell therapy to human clinical organ transplantation. This cooperative project aims at developing and trialling various immunoregulatory cell products in organ transplantation recipients, allowing a direct comparison of the safety, clinical practicality and therapeutic efficacy of each cell type." Quelle: Öffnet externen Link im aktuellen FensterThe One Study



Beteiligte Gruppen des RCIS:


Prof. Dr. Birgit Sawitzki
Institut für Medizinische Immunologie
AG Transplantationstoleranz



Projekt: Bio-DrIM

“Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation”


"The central focus of the project is the implementation of biomarker-driven strategies for personalizing immunosuppression (IS) to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) /1000 (trial) patients."




Nach oben

ERA-NET – Infect-ERA

"Infect-ERA is an ERA-NET on human infectious diseases funded under the Seventh Research Framework Programme (2013 – 2016). To date, it is a consortium of 14 partners from 11 countries. It is a continuation of the ERA-NET PathoGenoMics"
Quelle: Öffnet externen Link im aktuellen FensterInfect-ERA



Beteiligte Gruppen des RCIS:


Dr. Leif Erik Sander

Medizinische Klinik mit Schwerpunkt für Infektiologie und Pneumologie
AG Sander


Projekt: "Haplo Infect"
Multidrug resistant bacterial infections are on the rise while antibiotic pipelines are drying out. This global threat urgently calls for novel antimicrobial therapies. Adjuvant immunotherapy represents a promising strategy to combat infections without fueling drug resistance. For this to work, protective immune responses must be scaled to the level of infectious threats (Blander and Sander Nat Rev Immunol 2012), thus allowing for efficient pathogen clearance while minimizing inflammation-induced tissue damage. However, the cellular machinery that accurately assesses these infectious threats in humans as well as the precise contribution of bacterial factors is not well understood.


We will exploit a unique approach and perform a genome-wide screen using haploid human immune cells (Carette et al. Science 2009) in which genes will be disrupted at saturating scale using gene trap mutagenesis (Carette et al. Nat Biotechnol 2011). The biological in vivo function of selected target molecules will be investigated in relevant mouse models of infectious diseases.

Using these screens we will focus on the inflammatory response to medically relevant pathogens and a selected set of PAMPs, such as cell wall extracts and bacterial nucleic acid preparations, known to signify bacterial viability (i.e. threat).




Nach oben

Internationale Kooperationen


Systems Biology Tools Development For Cell Therapy And Drug Development

"SYSTHER is a virtual institute consisting of partners from Germany and Slovenia. It was established to investigate and improve solid tumor treatment based on systems biology approaches. Identification of target genes and proteins, and subsequent mathematical modeling of candidate pathways, intracellular networks and interaction dynamics of immunocompetent, tumor, and stem cell aim at elucidating mechanisms of tumor immunomodulation and the role of tumor stem cells in solid, non-metastasizing tumors, improving thus therapeutic strategies. Serum antibody profiling and gene expression analysis of tumor and stem cells shall further lead to the understanding of immunolodulation mechanisms." Quelle: Öffnet externen Link im aktuellen FensterSysther 


Beteiligte Gruppen des RCIS:


Dr. Michal Or-Guil

Humboldt Universität zu Berlin 

Institut für Biologie

AG Systemimmunologie



Projekt:  Systems Biology Tools 

"Systems biology is a very promising tool for studying biological problems, dealing with it in the most general way possible. It is thus connected to gathering of immense amounts of data that have strong dimensionality problem, representing a challenge both to biologists as well as to statisticians.

The aim of the work carried out in this work package is to prepare systems for identification of marker genes and for studying mechanisms of drug action in a an easy-to-use tools organised in flow charts or decision trees that would enable studies of different cases. Particular attention will be focused to the artillery of cytokines that are related to tumor immunosupression." Quelle: Öffnet externen Link im aktuellen FensterWP1


Nach oben


Kirsten Kindler
Kommunikation und Finanzen
t: +49 30 450 513 302
Dr. Ute Hoffmann
Redaktion und Webmaster
t: +49 30 28460658
Das ist das LOGO vom RCIS der Charité